CA2155554A1 - Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci - Google Patents
Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ciInfo
- Publication number
- CA2155554A1 CA2155554A1 CA002155554A CA2155554A CA2155554A1 CA 2155554 A1 CA2155554 A1 CA 2155554A1 CA 002155554 A CA002155554 A CA 002155554A CA 2155554 A CA2155554 A CA 2155554A CA 2155554 A1 CA2155554 A1 CA 2155554A1
- Authority
- CA
- Canada
- Prior art keywords
- ubiquitin
- inhibitor
- cells
- cleavage
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1606693A | 1993-02-10 | 1993-02-10 | |
US08/016,066 | 1993-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2155554A1 true CA2155554A1 (fr) | 1994-08-18 |
Family
ID=21775196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002155554A Abandoned CA2155554A1 (fr) | 1993-02-10 | 1994-01-27 | Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0684829A4 (fr) |
JP (1) | JPH08507754A (fr) |
AU (1) | AU676721B2 (fr) |
CA (1) | CA2155554A1 (fr) |
WO (1) | WO1994017816A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6287569B1 (en) | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
CA2219867A1 (fr) * | 1997-10-31 | 1999-04-30 | Jiangping Wu | Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique |
US5968747A (en) * | 1997-12-12 | 1999-10-19 | Incyte Pharmaceuticals, Inc. | Ubiquitin-like conjugating protein |
FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
KR20010080267A (ko) | 1998-10-20 | 2001-08-22 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아솜 억제제 약물 작용을 모니터링하는 방법 |
JP2002105080A (ja) * | 2000-09-29 | 2002-04-10 | Microbial Chem Res Found | 生理活性物質パネポフェナンスリンとその製造法 |
US20050049294A1 (en) | 2003-06-20 | 2005-03-03 | Michael Palladino | Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
CN102725300B (zh) | 2009-12-22 | 2015-03-11 | 赛福伦公司 | 蛋白酶体抑制剂及其制备、纯化、和应用的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4390629A (en) * | 1981-03-30 | 1983-06-28 | President And Fellows Of Harvard College | Polypeptide degrading enzymes |
US5340736A (en) * | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
-
1994
- 1994-01-27 EP EP94908690A patent/EP0684829A4/fr not_active Withdrawn
- 1994-01-27 JP JP6518184A patent/JPH08507754A/ja active Pending
- 1994-01-27 AU AU61691/94A patent/AU676721B2/en not_active Ceased
- 1994-01-27 WO PCT/US1994/001183 patent/WO1994017816A1/fr not_active Application Discontinuation
- 1994-01-27 CA CA002155554A patent/CA2155554A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0684829A4 (fr) | 1997-05-21 |
AU6169194A (en) | 1994-08-29 |
JPH08507754A (ja) | 1996-08-20 |
EP0684829A1 (fr) | 1995-12-06 |
AU676721B2 (en) | 1997-03-20 |
WO1994017816A1 (fr) | 1994-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tschopp et al. | Perforin-mediated target cell lysis by cytolytic T lymphocytes | |
Mueller et al. | Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. | |
US5759994A (en) | Recombinant thrombin receptor and related pharmaceuticals | |
US6325989B1 (en) | Form of dipeptidylpeptidase IV (CD26) found in human serum | |
US20070128198A1 (en) | Compositions comprising antibodies to human fgl2 | |
CA2270291A1 (fr) | Kallikreine specifique de la prostate | |
CA2155554A1 (fr) | Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci | |
WO1993024634A1 (fr) | Dipeptidyle peptidase-i, son clonage et agents therapeutiques contenant des inhibiteurs de cette substance | |
RU2194713C2 (ru) | Модифицированный c3 белок человека, фрагмент днк, конъюгат, фармацевтическая композиция, способ уменьшения количества белка | |
CA2136981A1 (fr) | Adn codant pour l'enzyme de conversion de l'interleukine 1.beta. precurseur | |
US6451759B1 (en) | Noncleavable Fas ligand | |
AU711586B2 (en) | Mocarhagin, a cobra venom protease, and therapeutic uses thereof | |
JP2003313199A (ja) | コラーゲン誘発血小板凝集抑制剤 | |
WO1998002579A1 (fr) | Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere | |
Raju et al. | Myristoyl-CoA: ProteinN-Myristoyltransferase from Bovine Cardiac Muscle: Molecular Cloning, Kinetic Analysis, andin VitroProteolytic Cleavage bym-Calpain | |
WO1998002579A9 (fr) | Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere | |
Fruth et al. | The T cell‐specific serine proteinase TSP‐1 is associated with cytoplasmic granules of cytolytic T lymphocytes | |
WO2000063227A1 (fr) | Variante d'epissage de metalloproteinase-5 (mt-mmp5-l) de matrice humaine de type membrane | |
Shibata et al. | Disruption of structural and functional integrity of α2‐macroglobulin by cathepsin E | |
AU732547B2 (en) | Novel cyclin-selective ubiquitin carrier polypeptides | |
US6558900B2 (en) | Regulation of apoptosis and in vitro model for studies thereof | |
US6180379B1 (en) | Cyclin-selective ubiquitin carrier polypeptides | |
Jackson et al. | Assembly and intracellular transport of MHC class I and class II molecules | |
AU6914600A (en) | Peptide and peptide analogues for the treatment and prevention of diabetes | |
AU727222B2 (en) | Regulation of apoptosis and in vitro model for studies thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |